Page 106 - 《中国药房》2025年15期

sis and management[J]. Expert Opin Drug Saf，2017，16 [16] TERICO A T，GALLAGHER J C. Beta-lactam hypersensi‐
（2）：139-147. tivity and cross-reactivity[J]. J Pharm Pract，2014，27（6）：
[ 4 ] WEI B M，FOX L P，KAFFENBERGER B H，et al. Drug- 530-544.
induced hypersensitivity syndrome/drug reaction with eo‐ [17] SODHI M，AXTELL S S，CALLAHAN J，et al. Is it safe
sinophilia and systemic symptoms. Part Ⅰ. Epidemiology， to use carbapenems in patients with a history of allergy to
pathogenesis，clinicopathological features，and prognosis penicillin? [J]. J Antimicrob Chemother，2004，54（6）：
[J]. J Am Acad Dermatol，2024，90（5）：885-908. 1155-1157.
[ 5 ] SHIOHARA T，KANO Y. A complex interaction between [18] USHIGOME Y，KANO Y，ISHIDA T，et al. Short- and
drug allergy and viral infection[J]. Clin Rev Allergy Im‐ long-term outcomes of 34 patients with drug-induced hy‐
munol，2007，33（1/2）：124-133. persensitivity syndrome in a single institution[J]. J Am
[ 6 ] 中国医师协会皮肤科医师分会变态反应性疾病专业委 Acad Dermatol，2013，68（5）：721-728.
员会. 药物超敏反应综合征诊治专家共识[J]. 中华皮肤 [19] HUSAIN Z，REDDY B Y，SCHWARTZ R A. DRESS syn‐
科杂志，2018，51（11）：787-790. drome：part Ⅱ . management and therapeutics[J]. J Am
[ 7 ] MCCORMACK M，ALFIREVIC A，BOURGEOIS S， Acad Dermatol，2013，68（5）：709.
et al. HLA-A*3101 and carbamazepine-induced hypersen‐ [20] BRIN C，BERNIGAUD C，HUA C，et al. Impact of sys‐
sitivity reactions in Europeans[J]. N Engl J Med，2011， temic to topical steroids switch on the outcome of drug re‐
364（12）：1134-1143. action with eosinophilia and systemic symptoms
[ 8 ] MIYAGAWA F，NAKAMURA Y，MIYASHITA K，et al. （DRESS）：a monocenter retrospective study of 20 cases
Preferential expression of CD134，an HHV-6 cellular re‐ [J]. Ann Dermatol Venereol，2021，148（3）：168-171.
[21] TOHYAMA M，HASHIMOTO K，ODA F，et al. Influence
ceptor，on CD4T cells in drug-induced hypersensitivity
of corticosteroid therapy on viral reactivation in drug-
syndrome （DIHS）/drug reaction with eosinophilia and
induced hypersensitivity syndrome/drug reaction with eo‐
systemic symptoms （DRESS）[J]. J Dermatol Sci，2016，
sinophilia and systemic symptoms[J]. J Dermatol，2020，
83（2）：151-154.
47（5）：476-482.
[ 9 ] MIYAGAWA F，NAKAMURA-NISHIMURA Y，KANATANI
[22] FUNCK-BRENTANO E，DUONG T A，BOUVRESSE S，
Y，et al. Correlation between expression of CD134，a hu‐
et al. Therapeutic management of DRESS：a retrospective
man herpesvirus 6 cellular receptor，on CD4 T cells and
+
study of 38 cases[J]. J Am Acad Dermatol，2015，72（2）：
Th2-type immune responses in drug-induced hypersensi‐
246-252.
tivity syndrome/drug reaction with eosinophilia and sys‐
[23] ICHAI P，LAURENT-BELLUE A，SALIBA F，et al.
temic symptoms[J]. Acta Derm Venereol，2020，100（6）：
adv00102. Acute liver failure/injury related to drug reaction with eo‐
sinophilia and systemic symptoms：outcomes and prognos‐
[10] SHIOHARA T，IIJIMA M，IKEZAWA Z，et al. The diag‐
tic factors[J]. Transplantation，2017，101（8）：1830-1837.
nosis of a DRESS syndrome has been sufficiently estab‐
[24] SIM D W，YU J，KOH Y I. Efficacy of add-on therapy
lished on the basis of typical clinical features and viral re‐
with intravenous immunoglobulin in steroid hyporespon‐
activations[J]. Br J Dermatol，2007，156（5）：1083-1084.
sive DRESS syndrome[J]. Clin Transl Sci，2022，15（3）：
[11] PEYRIÈRE H，DEREURE O，BRETON H，et al. Variability
782-788.
in the clinical pattern of cutaneous side-effects of drugs [25] JOLY P，JANELA B，TETART F，et al. Poor benefit/risk
with systemic symptoms：does a DRESS syndrome really
balance of intravenous immunoglobulins in DRESS[J].
exist?[J]. Br J Dermatol，2006，155（2）：422-428.
Arch Dermatol，2012，148（4）：543-544.
[12] PEREZ-INESTROSA E，SUAU R，MONTAÑEZ M I，
[26] NGUYEN E，YANES D，IMADOJEMU S，et al. Evalua‐
et al. Cephalosporin chemical reactivity and its immuno‐ tion of cyclosporine for the treatment of DRESS syndrome
logical implications[J]. Curr Opin Allergy Clin Immunol， [J]. JAMA Dermatol，2020，156（6）：704-706.
2005，5（4）：323-330. [27] GSCHWEND A，HELBLING A，FELDMEYER L，et al.
[13] ROMANO A，GAETA F，VALLUZZI R L，et al. IgE- Treatment with IL5-/IL-5 receptor antagonists in drug re‐
mediated hypersensitivity to cephalosporins： cross- action with eosinophilia and systemic symptoms
reactivity and tolerability of alternative cephalosporins[J]. （DRESS）[J]. Allergo J Int，2022，23：1-8.
J Allergy Clin Immunol，2015，136（3）：685-691. [28] KIM D，KOBAYASHI T，VOISIN B，et al. Targeted
[14] ZAGURSKY R J，PICHICHERO M E. Cross-reactivity in therapy guided by single-cell transcriptomic analysis in
β-lactam allergy[J]. J Allergy Clin Immunol Pract，2018，6 drug-induced hypersensitivity syndrome：a case report[J].
（1）：72-81. Nat Med，2020，26（2）：236-243.
[15] LEE Y M，BRADLEY N. Overview and insights into car‐ （收稿日期：2025-03-09 修回日期：2025-07-22）
bapenem allergy[J]. Pharmacy （Basel），2019，7（3）：110. （编辑：舒安琴）

· 1920 · China Pharmacy 2025 Vol. 36 No. 15 中国药房 2025年第36卷第15期